NO962848D0 - Monohydrat av (E)-2'-deoksy-2'-(fluormetylen)cytidin - Google Patents
Monohydrat av (E)-2'-deoksy-2'-(fluormetylen)cytidinInfo
- Publication number
- NO962848D0 NO962848D0 NO962848A NO962848A NO962848D0 NO 962848 D0 NO962848 D0 NO 962848D0 NO 962848 A NO962848 A NO 962848A NO 962848 A NO962848 A NO 962848A NO 962848 D0 NO962848 D0 NO 962848D0
- Authority
- NO
- Norway
- Prior art keywords
- fluoromethylene
- cytidine
- deoxy
- monohydrate
- neoplastic
- Prior art date
Links
- 150000004682 monohydrates Chemical class 0.000 title abstract 2
- XPYQFIISZQCINN-QVXDJYSKSA-N 4-amino-1-[(2r,3e,4s,5r)-3-(fluoromethylidene)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;hydrate Chemical compound O.O=C1N=C(N)C=CN1[C@H]1C(=C/F)/[C@H](O)[C@@H](CO)O1 XPYQFIISZQCINN-QVXDJYSKSA-N 0.000 title 1
- 229940123934 Reductase inhibitor Drugs 0.000 abstract 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 abstract 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- GFFXZLZWLOBBLO-ASKVSEFXSA-N tezacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=C/F)/[C@H](O)[C@@H](CO)O1 GFFXZLZWLOBBLO-ASKVSEFXSA-N 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17895294A | 1994-01-07 | 1994-01-07 | |
| PCT/US1994/014648 WO1995018815A1 (en) | 1994-01-07 | 1994-12-13 | Monohydrate of (e)-2'-deoxy-2'-(fluoromethylene)cytidine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO962848D0 true NO962848D0 (no) | 1996-07-05 |
| NO962848L NO962848L (no) | 1996-09-06 |
| NO306409B1 NO306409B1 (no) | 1999-11-01 |
Family
ID=22654587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO962848A NO306409B1 (no) | 1994-01-07 | 1996-07-05 | Monohydrat av (E)-2'-deoxy-2'-(fluormethylen)cytidin |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0738273B1 (no) |
| JP (1) | JPH09511227A (no) |
| KR (1) | KR100330328B1 (no) |
| CN (1) | CN1043231C (no) |
| AT (1) | ATE186732T1 (no) |
| AU (1) | AU684604B2 (no) |
| CA (1) | CA2179987C (no) |
| DE (1) | DE69421721T2 (no) |
| DK (1) | DK0738273T3 (no) |
| ES (1) | ES2141330T3 (no) |
| FI (1) | FI114396B (no) |
| GR (1) | GR3032614T3 (no) |
| HU (1) | HU217849B (no) |
| IL (1) | IL112242A (no) |
| MX (1) | MX9500363A (no) |
| NO (1) | NO306409B1 (no) |
| NZ (1) | NZ279030A (no) |
| TW (1) | TW397838B (no) |
| WO (1) | WO1995018815A1 (no) |
| ZA (1) | ZA9512B (no) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2309350C (en) | 1997-11-12 | 2007-04-03 | Mitsubishi Chemical Corporation | Purine derivatives and medicaments comprising the same as active ingredient |
| KR100747106B1 (ko) | 1999-05-11 | 2007-08-08 | 미쯔비시 가가꾸 가부시끼가이샤 | 퓨린 유도체 이수화물, 이를 유효성분으로 함유하는 의약및 이의 제조 중간체 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2002648C (en) * | 1988-11-15 | 2000-02-29 | James R. Mccarthy | 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives |
| FI95269C (fi) * | 1989-05-15 | 1996-01-10 | Squibb Bristol Myers Co | 2',3'-dideoksi-inosiinimonohydraatin, 2',3'-dideoksi-2',3'-didehydrot ymidiinimonohydraatin ja 2',3'-dideoksi-2'-fluori-inosiinihemihydraatin antiviraalisia, hyvin vesiliukoisia, stabiileja, kiteisiä suoloja |
| JPH0615557B2 (ja) * | 1990-02-19 | 1994-03-02 | ヤマサ醤油株式会社 | ２’―デオキシ―２’―メチリデンシチジンの２水和物結晶 |
| CA2133961C (en) * | 1992-05-12 | 1998-03-31 | James R. Mccarthy | A process for the preparation of ribonucleotide reductase inhibitors |
-
1994
- 1994-12-13 CN CN94194779A patent/CN1043231C/zh not_active Expired - Fee Related
- 1994-12-13 NZ NZ279030A patent/NZ279030A/en unknown
- 1994-12-13 DK DK95907232T patent/DK0738273T3/da active
- 1994-12-13 ES ES95907232T patent/ES2141330T3/es not_active Expired - Lifetime
- 1994-12-13 DE DE69421721T patent/DE69421721T2/de not_active Expired - Fee Related
- 1994-12-13 EP EP95907232A patent/EP0738273B1/en not_active Expired - Lifetime
- 1994-12-13 JP JP7518503A patent/JPH09511227A/ja active Pending
- 1994-12-13 CA CA002179987A patent/CA2179987C/en not_active Expired - Fee Related
- 1994-12-13 AT AT95907232T patent/ATE186732T1/de not_active IP Right Cessation
- 1994-12-13 KR KR1019960703658A patent/KR100330328B1/ko not_active Expired - Fee Related
- 1994-12-13 HU HU9601848A patent/HU217849B/hu not_active IP Right Cessation
- 1994-12-13 WO PCT/US1994/014648 patent/WO1995018815A1/en not_active Ceased
- 1994-12-13 AU AU15532/95A patent/AU684604B2/en not_active Ceased
-
1995
- 1995-01-03 ZA ZA9512A patent/ZA9512B/xx unknown
- 1995-01-04 TW TW084100012A patent/TW397838B/zh not_active IP Right Cessation
- 1995-01-04 IL IL11224295A patent/IL112242A/xx not_active IP Right Cessation
- 1995-01-06 MX MX9500363A patent/MX9500363A/es unknown
-
1996
- 1996-07-05 FI FI962769A patent/FI114396B/fi active IP Right Grant
- 1996-07-05 NO NO962848A patent/NO306409B1/no unknown
-
2000
- 2000-02-09 GR GR20000400313T patent/GR3032614T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100330328B1 (ko) | 2002-12-05 |
| EP0738273B1 (en) | 1999-11-17 |
| HUT75055A (en) | 1997-03-28 |
| AU1553295A (en) | 1995-08-01 |
| EP0738273A1 (en) | 1996-10-23 |
| DE69421721T2 (de) | 2000-04-27 |
| CN1141045A (zh) | 1997-01-22 |
| CA2179987A1 (en) | 1995-07-13 |
| HU9601848D0 (en) | 1996-09-30 |
| NO962848L (no) | 1996-09-06 |
| GR3032614T3 (en) | 2000-05-31 |
| CN1043231C (zh) | 1999-05-05 |
| JPH09511227A (ja) | 1997-11-11 |
| FI114396B (fi) | 2004-10-15 |
| DE69421721D1 (de) | 1999-12-23 |
| IL112242A (en) | 2000-08-31 |
| NO306409B1 (no) | 1999-11-01 |
| AU684604B2 (en) | 1997-12-18 |
| MX9500363A (es) | 1998-04-30 |
| FI962769L (fi) | 1996-07-05 |
| ZA9512B (en) | 1995-09-11 |
| CA2179987C (en) | 1999-01-19 |
| ATE186732T1 (de) | 1999-12-15 |
| HU217849B (hu) | 2000-04-28 |
| TW397838B (en) | 2000-07-11 |
| DK0738273T3 (da) | 2000-04-17 |
| WO1995018815A1 (en) | 1995-07-13 |
| ES2141330T3 (es) | 2000-03-16 |
| NZ279030A (en) | 1997-05-26 |
| FI962769A0 (fi) | 1996-07-05 |
| IL112242A0 (en) | 1995-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9811121A (pt) | Produto, composição farmacêutica, e uso de um produto | |
| TR199701212T1 (xx) | �drar� tutamama halinin tedavisi i�in alfa IL- agonistlerinin kullan�lmas�. | |
| CA2002648A1 (en) | 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives | |
| DK0755249T3 (da) | Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom | |
| SE9500566D0 (sv) | L-plate | |
| ES2191292T3 (es) | Compuestos antivirales poliaromaticos. | |
| NO306409B1 (no) | Monohydrat av (E)-2'-deoxy-2'-(fluormethylen)cytidin | |
| DE69521122D1 (de) | 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze | |
| IE893080L (en) | Novel 2'-halomethylidene,2'-ethenylidene and¹2'-ethynyl adenosine derivatives | |
| EP0347852A3 (en) | Novel neplanocin derivatives | |
| BR9811643A (pt) | Suplementação quìmica de osso | |
| MY124071A (en) | Treatment of viral disease in swine | |
| BR9916043A (pt) | Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes | |
| DE69836087D1 (de) | Kortikalknochenimplantat für wirbelfusion nach smith-robinson | |
| DK0459176T3 (da) | Oligophosphater med antiviral virkning | |
| GR3034688T3 (en) | Use of 6,7-substituted-2-aminotetralines for preparing pharmaceutical compositions useful for the treatment of septic shock, and antipyretic and antiinflammatory pharmaceutical compositions | |
| ES2085023T3 (es) | Procedimientos para la produccion de zidovudina. | |
| BR0012380A (pt) | 2-amino-benzoxazinonas para o tratamento de vìrus do herpes simples | |
| SE9403861D0 (sv) | Novel medicinal use | |
| AR015724A1 (es) | La utilizacion de un inhibidor del intercambiador entre na+ y h+ para la preparacion de un medicamento destinado al tratamiento o a la profilaxia deenfermedades del sistema nervioso central. | |
| ES2181160T3 (es) | Derivados de 1,4-dihidropiridina y su utilizacion en terapia. | |
| LTIP1943A (en) | Arylating agents, used in the treatment of cancerand disease caused by viral infection | |
| BR9906931A (pt) | Triazepinonas, processo para sua preparação e sua aplicação terapêutica | |
| ITCA950008A0 (it) | Impiego di combinaqzioni di analoghi di nucleosidi nella terapia delleinfezioni dell'aids. | |
| UA22189A (uk) | Іі-кабетоксифеhілакоhітімід, який виявляє активhість відhосhо вірусу везикулярhого стоматиту та вірусу простого герпесу |